12.23  1.23 (11.18%)		12-15 15:59
Open: 11.82 High: 12.5 Volume: 147,417		Pre. Close: 11 Low: 10.9189 Market Cap: 25(M)

Short term
Mid term
Targets	6-month :	15.19	1-year :	17.74
Resists	First :	13.01	Second :	15.19
Pivot price	10.09
Supports	First :	9.98	Second :	8.11
MAs	MA(5) :	11.06	MA(20) :	10.38
	MA(100) :	12.29	MA(250) :	0
MACD	MACD :	-0.3	Signal :	-0.6
%K %D	K(14,3) :	80.7	D(3) :	73.2
RSI	RSI(14): 58.9
52-week	High :	22.9	Low :	8.11

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CVKD ] has closed Bollinger Bands are 53.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	12.52 - 12.56	12.56 - 12.6
Low:	10.81 - 10.86	10.86 - 10.9
Close:	12.14 - 12.23	12.23 - 12.3

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Tue, 18 Nov 2025
Cadrenal Therapeutics Announces New Stock Offering Program - TipRanks

Mon, 10 Nov 2025
Cadrenal (NASDAQ: CVKD) adds Phase 2-ready frunexian; updates cGMP tecarfarin - Stock Titan

Tue, 07 Oct 2025
Cadrenal therapeutics CFO Szot sells $1496 in shares - Investing.com

Fri, 26 Sep 2025
Szot, CFO of Cadrenal, sells $174k in CVKD stock - Investing.com

Mon, 11 Aug 2025
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Business Wire

Thu, 08 May 2025
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	2 (M)
Shares Float	2 (M)
Held by Insiders	25.6 (%)
Held by Institutions	9.3 (%)
Shares Short	34 (K)
Shares Short P.Month	28 (K)

EPS	-8.73
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.33
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-209.3 %
Return on Equity (ttm)	-468.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-7.06
Qtrly Earnings Growth	0 %
Operating Cash Flow	-12 (M)
Levered Free Cash Flow	-7 (M)

PE Ratio	-1.41
PEG Ratio	0
Price to Book value	9.19
Price to Sales	0
Price to Cash Flow	-2.16

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.